PLAQUENIL 200 mg

DRUG4 trials

Sponsors

Hospices Civils De Lyon, Assistance Publique Hopitaux De Paris, Universitair Medisch Centrum Utrecht, Centre Hospitalier Universitaire De Toulouse

Conditions

Extra pulmonary sarcoidosisPrimary Sjogren's syndromemastocytosisprimary Sjögren's Syndrome

Phase 2

NECESSITY – « New Clinical End-points in patients with primary Sjögren’s Syndrome: an Interventional Trial based on stratifYing patients »

Active, not recruitingCTIS2023-510054-16-00

Assistance Publique Hopitaux De ParisPrimary Sjogren's syndrome

Start: 2022-04-26Target: 235Updated: 2025-04-22

Leflunomide and Hydroxychloroquine combination therapy for primary Sjögren’s Syndrome; RepurpSS-II study

CompletedCTIS2024-510904-36-00

Universitair Medisch Centrum Utrechtprimary Sjögren's Syndrome

Start: 2021-10-12End: 2025-06-03Target: 52Updated: 2024-06-11

Phase 3

HydroxyChloroquine as steroid-sparing Agent in Extra-pulmonary SARcoidosis. A multicenter, prospective, placebo-controlled, randomized trial. CAESAR

RecruitingCTIS2022-502155-65-00

Hospices Civils De LyonExtra pulmonary sarcoidosis

Start: 2024-07-30Target: 140Updated: 2025-06-27

Hydroxychloroquine in isolated cutaneous mastocytosis patients or indolent systemic mastocytosis with associated skin involvement patients: proof of concept study (HCQMa)

RecruitingCTIS2024-518594-33-00

Centre Hospitalier Universitaire De Toulousemastocytosis

Start: 2021-11-18Target: 30Updated: 2025-10-03